Clinical Trial Detail

NCT ID NCT03483012
Title Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab

Age Groups: adult senior

No variant requirements are available.